Discover 381 paid clinical trials in Greenville, South Carolina. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 381
CGM for Management of Type 2 Diabetes in Pregnancy
for
Type 2 Diabetes Mellitus (T2DM), Pregnancy
Location: Greenville SC, Chapel Hill NC, Birmingham AL,
Sponsor: University of Alabama at Birmingham
Sex: Female
Age: 18 - 50
Code: NCT06628453
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
for
Diffuse Large B-Cell Lymphoma
Location: Greenville SC, Athens GA, Knoxville TN, Roanoke VA,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06717347
Phase 3, Recruiting
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
for
AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar,
Location: Greenville SC, Charlotte NC, Augusta GA, Atlanta GA,
Sponsor: Kura Oncology, Inc.
Sex: All
Age: 18+
Code: NCT06001788
Phase 1, Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Get alerts for new trials in your area by subscribing now
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
for
Muscle Invasive Bladder Urothelial Carcinoma,
Location: Greenville SC, Greer SC, Easley SC, Anderson SC,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT05987241
Phase 2, Phase 3, Recruiting
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
for
Intracerebral Hemorrhage, Atrial Fibrillation
Location: Greenville SC, Charlotte NC, Augusta GA, Knoxville TN,
Sponsor: Yale University
Sex: All
Age: 18+
Code: NCT03907046
Phase 3, Recruiting
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
for
Smoldering Plasma Cell Myeloma
Location: Greenville SC, Greer SC, Seneca SC, Atlanta GA,
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All
Age: 18+
Code: NCT03937635
Phase 3, Recruiting
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
for
Recurrent Lung Non-Small Cell Carcinoma,
Location: Greenville SC, Greer SC, Easley SC, Anderson SC,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT05642572
Phase 2, Recruiting
Project: Every Child for Younger Patients With Cancer
for
Adrenal Gland Pheochromocytoma, Carcinoma In Situ,
Location: Greenville SC, Asheville NC, Charlotte NC, Columbia SC,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 25
Code: NCT02402244
Recruiting
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
for
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Location: Greenville SC, Atlanta GA, Charleston SC, Durham NC,
Sponsor: Translational Sciences, Inc.
Sex: All
Age: 18+
Code: NCT05948566
Phase 2, Recruiting
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
for
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8,
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab